Last reviewed · How we verify
Insulin Lispro-aabc
Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
Insulin Lispro-aabc is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro-aabc |
|---|---|
| Also known as | LY900014 |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Lispro-aabc is a biosynthetic insulin analog engineered with amino acid substitutions (aabc denotes the specific modifications) that allow faster absorption and onset of action compared to human insulin. It mimics endogenous insulin by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production. The rapid kinetics make it suitable for mealtime insulin therapy in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes (PHASE1)
- A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (PHASE4)
- Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev® (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |